Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.Coronary Vessels: The veins and arteries of the HEART.Coronary Angiography: Radiography of the vascular system of the heart muscle after injection of a contrast medium.Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.Coronary Circulation: The circulation of blood through the CORONARY VESSELS of the HEART.Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.Angioplasty, Balloon, Coronary: Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.Hirudin Therapy: Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.DibenzothiepinsDogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Fibrinolytic Agents: Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.Coronary Stenosis: Narrowing or constriction of a coronary artery.Thromboxane-A Synthase: An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5.Coronary Artery Bypass: Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.Platelet Aggregation: The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.Platelet Aggregation Inhibitors: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.Tissue Plasminogen Activator: A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Sinus Thrombosis, Intracranial: Formation or presence of a blood clot (THROMBUS) in the CRANIAL SINUSES, large endothelium-lined venous channels situated within the SKULL. Intracranial sinuses, also called cranial venous sinuses, include the superior sagittal, cavernous, lateral, petrous sinuses, and many others. Cranial sinus thrombosis can lead to severe HEADACHE; SEIZURE; and other neurological defects.Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.Platelet Glycoprotein GPIIb-IIIa Complex: Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Thrombolytic Therapy: Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Coronary Vasospasm: Spasm of the large- or medium-sized coronary arteries.Intracranial Thrombosis: Formation or presence of a blood clot (THROMBUS) in a blood vessel within the SKULL. Intracranial thrombosis can lead to thrombotic occlusions and BRAIN INFARCTION. The majority of the thrombotic occlusions are associated with ATHEROSCLEROSIS.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Acute Disease: Disease having a short and relatively severe course.Carotid Artery Thrombosis: Blood clot formation in any part of the CAROTID ARTERIES. This may produce CAROTID STENOSIS or occlusion of the vessel, leading to TRANSIENT ISCHEMIC ATTACK; CEREBRAL INFARCTION; or AMAUROSIS FUGAX.Coronary Aneurysm: Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.Electrocardiography: Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.Coronary Occlusion: Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Stents: Devices that provide support for tubular structures that are being anastomosed or for body cavities during skin grafting.Percutaneous Coronary Intervention: A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting.Anticoagulants: Agents that prevent clotting.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Phlebography: Radiographic visualization or recording of a vein after the injection of contrast medium.Sagittal Sinus Thrombosis: Formation or presence of a blood clot (THROMBUS) in the SUPERIOR SAGITTAL SINUS or the inferior sagittal sinus. Sagittal sinus thrombosis can result from infections, hematological disorders, CRANIOCEREBRAL TRAUMA; and NEUROSURGICAL PROCEDURES. Clinical features are primarily related to the increased intracranial pressure causing HEADACHE; NAUSEA; and VOMITING. Severe cases can evolve to SEIZURES or COMA.Coronary Care Units: The hospital unit in which patients with acute cardiac disorders receive intensive care.Intracranial Embolism and Thrombosis: Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures.Ultrasonography, Interventional: The use of ultrasound to guide minimally invasive surgical procedures such as needle ASPIRATION BIOPSY; DRAINAGE; etc. Its widest application is intravascular ultrasound imaging but it is useful also in urology and intra-abdominal conditions.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Femoral Vein: The vein accompanying the femoral artery in the same sheath; it is a continuation of the popliteal vein and becomes the external iliac vein.Iliac Vein: A vein on either side of the body which is formed by the union of the external and internal iliac veins and passes upward to join with its fellow of the opposite side to form the inferior vena cava.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Upper Extremity Deep Vein Thrombosis: DEEP VEIN THROMBOSIS of an upper extremity vein (e.g., AXILLARY VEIN; SUBCLAVIAN VEIN; and JUGULAR VEINS). It is associated with mechanical factors (Upper Extremity Deep Vein Thrombosis, Primary) secondary to other anatomic factors (Upper Extremity Deep Vein Thrombosis, Secondary). Symptoms may include sudden onset of pain, warmth, redness, blueness, and swelling in the arm.Calcinosis: Pathologic deposition of calcium salts in tissues.Hemostasis: The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.Myocardial Revascularization: The restoration of blood supply to the myocardium. (From Dorland, 28th ed)Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.Recurrence: The return of a sign, symptom, or disease after a remission.Hemorrhage: Bleeding or escape of blood from a vessel.Thrombectomy: Surgical removal of an obstructing clot or foreign material from a blood vessel at the point of its formation. Removal of a clot arising from a distant site is called EMBOLECTOMY.Portal Vein: A short thick vein formed by union of the superior mesenteric vein and the splenic vein.Coronary Artery Bypass, Off-Pump: Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart and lungs through an oxygenator).Heparin, Low-Molecular-Weight: Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.Cerebral Veins: Veins draining the cerebrum.Hemodynamics: The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Cardiac Catheterization: Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.Blood Coagulation: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.Factor V: Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.Vasodilator Agents: Drugs used to cause dilation of the blood vessels.Graft Occlusion, Vascular: Obstruction of flow in biological or prosthetic vascular grafts.Blood Flow Velocity: A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.Cavernous Sinus Thrombosis: Formation or presence of a blood clot (THROMBUS) in the CAVERNOUS SINUS of the brain. Infections of the paranasal sinuses and adjacent structures, CRANIOCEREBRAL TRAUMA, and THROMBOPHILIA are associated conditions. Clinical manifestations include dysfunction of cranial nerves III, IV, V, and VI, marked periorbital swelling, chemosis, fever, and visual loss. (From Adams et al., Principles of Neurology, 6th ed, p711)Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.Vasodilation: The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.Bleeding Time: Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Vena Cava, Inferior: The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs.Antiphospholipid Syndrome: The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Fibrin Fibrinogen Degradation Products: Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.Swine: Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.Heart: The hollow, muscular organ that maintains the circulation of the blood.Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.Collateral Circulation: Maintenance of blood flow to an organ despite obstruction of a principal vessel. Blood flow is maintained through small vessels.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Myocardium: The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.Lateral Sinus Thrombosis: Formation or presence of a blood clot (THROMBUS) in the LATERAL SINUSES. This condition is often associated with ear infections (OTITIS MEDIA or MASTOIDITIS) without antibiotic treatment. In developed nations, lateral sinus thrombosis can result from CRANIOCEREBRAL TRAUMA; BRAIN NEOPLASMS; NEUROSURGICAL PROCEDURES; THROMBOPHILIA; and other conditions. Clinical features include HEADACHE; VERTIGO; and increased intracranial pressure.Platelet Activation: A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.Chest Pain: Pressure, burning, or numbness in the chest.Prothrombin: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.Vascular Patency: The degree to which BLOOD VESSELS are not blocked or obstructed.

Intravenous magnesium reduces infarct size after ischemia/reperfusion injury combined with a thrombogenic lesion in the left anterior descending artery. (1/1009)

Experimental studies have demonstrated that intravenous magnesium (Mg) can protect the ischemic myocardium and has an antithrombotic effect. In patients with myocardial infarction, the reperfusion injury is complicated by the presence of a thrombogenic area in the affected coronary artery that may cause repetitive thrombus formation and embolization. We investigated the effect of Mg on infarct size in a randomized study in pigs. Myocardial infarction was induced by a 50-minute mechanical occlusion of the left anterior descending artery combined with an arterial injury, which stimulated a dynamic thrombus formation with emboli shedding on reperfusion. Magnesium sulfate (6 mmol/20 min plus 3 mmol/h) or saline was started at 30 minutes after coronary occlusion. Real-time ventricular pressure-volume loops were generated from the left ventricle by using a microtip pressure manometer and a conductance catheter. Platelet accumulation in the myocardium was evaluated by using 111In-labeled platelets. After 4 hours of reperfusion, the infarct size/area at risk ratio in the placebo group was 46+/-0.06% (n=8) compared with 22+/-0.07% (n=6) in the Mg-treated animals (P=0. 03). Ejection fraction decreased significantly in the control group but not in the Mg-treated animals (P=0.03). Platelet accumulation in the myocardium did not change significantly between the Mg- and placebo-treated animals (placebo group, 191+/-19%; Mg group, 177+/-29%; NS). The present study demonstrates that intravenous Mg infusion is able to reduce infarct size by >50% and preserve the ejection fraction in this model where ischemia/reperfusion injury was evaluated in the presence of a thrombogenic area in the nutrient artery.  (+info)

A role for changes in platelet production in the cause of acute coronary syndromes. (2/1009)

Platelets are heterogeneous with respect to their size, density, and reactivity. Large platelets are more active hemostatically, and platelet volume has been found to be increased both in patients with unstable angina and with myocardial infarction. Furthermore, platelet volume is a predictor of a further ischemic event and death when measured after myocardial infarction. Platelets which are anucleate cells with no DNA are derived from their precursor, the megakaryocyte. Therefore, it is suggested that changes in platelet size are determined at thrombopoiesis in the megakaryocyte and that those changes might precede acute cardiac events. Understanding of the signaling system that controls platelet production may also further elucidate the cascade of events leading to acute vascular occlusion in some patients.  (+info)

Endothelial injuries of coronary arteries distal to thrombotic sites: role of adhesive interaction between endothelial P-selectin and leukocyte sialyl LewisX. (3/1009)

Intracoronary thrombus formation is associated with epicardial vasoconstriction distal to the thrombotic site. To investigate the mechanisms of abnormal vasomotor function of the artery distal to the thrombotic site, we studied coronary vessels in dogs with cyclic flow variations (CFVs) of the left anterior descending coronary artery (LAD) stenosis with endothelial injury. Coronary rings isolated from the LAD (proximal, stenotic, and distal sites) and control circumflex coronary arteries were tested for responsiveness to endothelium-dependent (acetylcholine and A23187) and endothelium-independent vasodilators (NaNO2). Endothelium-independent relaxation was intact in all 4 sites. Endothelium-dependent relaxation was intact in the control and proximal sites and impaired in the stenotic sites. Relaxations not only to acetylcholine and A23187 but also to serotonin, ADP, and thrombin were impaired in the distal sites after observing CFVs for 80 minutes. Electron microscopy revealed the loss of endothelial integrity with leukocyte adherence to the endothelium in the distal sites. Immunohistochemical expression of P-selectin on the endothelial cells was more upregulated in the distal site than in the proximal site, and P-selectin mRNA expression was significantly greater in the ischemic region distal to the thrombotic site than in the proximal nonischemic region. PB1.3, a neutralizing monoclonal antibody against P-selectin, and sialyl LewisX (SLeX)-containing oligosaccharide SLeX, a carbohydrate analogue of selectin ligand, preserved endothelial function without affecting CFVs. SLeX-containing oligosaccharide preserved endothelial integrity of the distal site and inhibited P-selectin expression of the distal site. Thus, the adhesive interaction between endothelial P-selectin and leukocyte SLeX may play an important role in endothelial injuries of the coronary artery distal to the thrombotic site.  (+info)

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. (4/1009)

The small molecule direct thrombin inhibitor L-374,087 was characterized across species in an in vitro activated partial thromboplastin clotting time (aPTT) assay and in vivo in rhesus monkey and dog thrombosis models. In vitro in rhesus, dog, and human plasma, L-374,087 concentrations eliciting 2-fold increases in aPTT were 0.25, 1.9, and 0.28 microM, respectively. In anesthetized rhesus monkeys, 300 microgram/kg bolus plus 12 microgram/kg/min and 300 microgram/kg bolus plus 30 microgram/kg/min L-374,087 i.v. infusions significantly reduced jugular vein thrombus extension, with both regimens limiting venous thrombus extension to 2-fold that of baseline thrombus mass compared with a 5-fold extension observed in the vehicle control group. Antithrombotic efficacy in the rhesus with the lower-dose regimen was achieved with 2.3- to 2.4-fold increases in aPTT and prothrombin time. In a conscious instrumented dog model of electrolytic vessel injury, the oral administration of two 10 mg/kg L-374,087 doses 12 h apart significantly reduced jugular vein thrombus mass, reduced the incidence of and delayed time to occlusive coronary artery thrombosis, and significantly reduced coronary artery thrombus mass and ensuing posterolateral myocardial infarct size. Antithrombotic efficacy in the dog was achieved with 1.6- to 2.0-fold increases in aPTT at 1 to 6 h after oral dosing with L-374,087. These results indicate significant antithrombotic efficacy against both venous and coronary arterial thrombosis with L-374,087 with only moderate elevations in aPTT or prothrombin time. The oral efficacy of L-374,087 characterizes this compound as a prototype for the further development of orally active direct thrombin inhibitors.  (+info)

Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. (5/1009)

OBJECTIVES: The objective of this prospective study was to evaluate the relation between high lipoprotein(a) levels and thrombotic and restenotic events after coronary stent implantation. BACKGROUND: Lipoprotein(a) may promote atherogenesis, coronary thrombosis and restenosis after balloon angioplasty, but the clinical significance remains unclear. METHODS: The study included 2,223 consecutive patients with successful coronary stent placement. According to the serum level of lipoprotein(a), patients were divided in two groups: 457 patients of the highest quintile formed the high lipoprotein(a) group, and 1,766 patients of the lower four quintiles formed the low lipoprotein(a) group. Primary end points were the incidence of angiographic restenosis at six months and the event-free survival at one year. Secondary end point was the incidence of angiographic stent occlusion. RESULTS: Early stent occlusion occurred in four of the 457 patients (0.9%) with high and 37 of the 1,766 patients (2.1%) with low lipoprotein(a) levels, odds ratio of 0.41 (95% confidence interval, 0.15 to 1.16). Angiographic restenosis occurred in 173 of the 523 lesions (33.2%) in the high lipoprotein(a) group and 636 of the 1,943 lesions (32.7%) in the low lipoprotein(a) group, odds ratio of 1.02 (0.83 to 1.25). The probability of event-free survival was 73.0% in the high lipoprotein(a) group and 74.8% in the low lipoprotein(a) group (p = 0.45). On the basis of the findings in the low lipoprotein(a) group, the power of this study to detect a 25% increase in the incidence of restenosis and adverse events in the group with elevated lipoprotein(a) was 90% and 75%, respectively. CONCLUSIONS: Elevated lipoprotein(a) levels did not influence the one-year clinical and angiographic outcome after stent placement. Thrombotic events and measures of restenosis were not adversely affected by the presence of high lipoprotein(a) levels.  (+info)

Antithrombin activity during the period of percutaneous coronary revascularization: relation to heparin use, thrombotic complications and restenosis. (6/1009)

OBJECTIVES: This study evaluated changes in antithrombin (AT) activity around the time of percutaneous transluminal coronary revascularization (PTCR) with unfractionated heparin anticoagulation and the effects these changes had on major thrombotic complications of PTCR. BACKGROUND: Heparin is used during PTCR to prevent thrombosis. However, heparin, a cofactor for AT, causes AT activity to fall. AT activity <70% is associated with thrombosis. There is a prothrombotic state after heparin discontinuation that has not been well explained. METHODS: Antithrombin activity was sampled at the start and end of PTCR and the next two mornings in 250 consecutive patients. We recorded occurrence of major thrombotic events, defined as 1) major thrombotic complications of PTCR; 2) major in-lab thrombus formation; or 3) subacute occlusion. Discriminant analysis was employed to evaluate the relationship of AT activity to these events. Change in AT activity and its relationship to heparin was evaluated. Evidence of restenosis at six months was obtained. RESULTS: There were 14 major thrombotic events. Antithrombin activity <70% was strongly (p = 0.006) associated with these events. The AT activity fell significantly through the morning after PTCR when 21% of patients had AT activity <70%; AT activity did not normalize until >20 h after heparin discontinuation. Pre-PTCR use of heparin led to lower AT activity in proportion to duration of heparin use. There was no relationship between AT activity and restenosis. CONCLUSIONS: Low AT activity may contribute to major thrombotic complications of PTCR. The way heparin is used before and after PTCR is important to development of low AT activity.  (+info)

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. (7/1009)

OBJECTIVES: The study sought to determine the effects of lipid-lowering with pravastatin on the systemic fibrinolytic profile and on thrombus formation under dynamic flow conditions. BACKGROUND: Lowering cholesterol (C) decreases clinical events in coronary artery disease (CAD) patients, but an analysis of the effects of lipid-lowering on the entire hemostatic and thrombotic profile has not been conducted. METHODS: We prospectively studied 93 stable patients with untreated low-density lipoprotein cholesterol (LDL-C) >145 mg/dl. The CAD patients received pravastatin, and non-CAD patients were randomized to pravastatin versus placebo (double-blind). Thrombus formation upon an injured vascular surface was assessed in a substudy of 40 patients with a previously validated ex vivo perfusion chamber system. Systemic hemostatic markers and thrombus formation were evaluated at baseline, three and six months. RESULTS: Placebo produced no changes in either the lipid profile, any of the hemostatic markers, or the ex vivo thrombus formation. Both pravastatin groups (CAD and non-CAD) showed decreased LDL-C by 30% within 6 weeks (188 to 126 mg/dl, p < 0.001 vs. baseline), and decreased plasminogen activator inhibitor-1 at 3- and 6-month follow-up compared to baseline (15% to 18% decrease at 3 months and 21% to 23% at 6 months). For the tissue plasminogen activator antigen, CAD and non-CAD groups showed significant decreases at 6 months compared to baseline (10% and 13%, respectively). No significant changes were observed with treatment in d-dimer, fibrinopeptide A, prothrombin fragment F1.2, factor VIIa, von Willebrand factor, or C-reactive protein. Fibrinogen levels were significantly increased at 6 months compared to baseline, though still below the upper normal limit. In the perfusion chamber substudy, there was a decrease in thrombus area in non-CAD patients treated with pravastatin at both 3 and 6 months compared to baseline (by 21% and 34%, respectively). The CAD patients showed decreases in thrombus formation by 13% at 3 months, and by 16% at 6 months. The change in LDL-C- correlated modestly with the change in thrombus formation (r = 0.49; p < 0.01). CONCLUSIONS: Pravastatin therapy significantly decreased thrombus formation and improved the fibrinolytic profile in patients with and without CAD. These early effects may, in part, explain the benefit rendered in primary and secondary prevention of CAD.  (+info)

Adhesive interaction between P-selectin and sialyl Lewis(x) plays an important role in recurrent coronary arterial thrombosis in dogs. (8/1009)

Cell adhesion molecules may play an important role in the disease process of acute coronary syndromes. We have shown a neutralizing anti-P-selectin monoclonal antibody and a sialyl Lewis(x)-containing oligosaccharide (SLe(x)-OS), an analogue of selectin ligand on leukocytes, reduce cyclic flow variations (CFVs) in a canine model of recurrent coronary arterial thrombosis, suggesting the important interaction between P-selectin and SLex for the pathophysiology of these syndromes. However, the functional role of these adhesion molecules in the thrombotic process remains unclear. Therefore, we investigated effects of SLe(x)-OS on CFVs, platelet P-selectin expression, and morphology of the stenotic site in the same model. Anesthetized open-chest dogs (n=34) were randomly divided into 4 groups after developing CFVs. Dogs intravenously received saline or graded doses of SLe(x)-OS (5, 20, or 40 mg/kg bolus) infusion followed by a continuous infusion (5 mg. kg-1. h-1) for 60 minutes. By flow cytometric analysis, P-selectin expression on platelets after CFVs was significantly upregulated during CFVs. Immunohistochemical analysis revealed the incorporation of platelets with upregulated P-selectin within thrombi at the stenotic site. Microscopic observations revealed the presence of numerous platelets adhered to leukocytes at the stenotic site on the damaged endothelium. SLe(x)-OS significantly reduced CFVs, inhibited the P-selectin expression on platelets, and prevented the adherence of platelets and leukocytes. These findings further support the notion that the adhesive interaction between P-selectin on platelets and SLe(x) on leukocytes plays an important role in platelet-mediated thrombus formation in this model.  (+info)

TY - JOUR. T1 - Molecular imaging identifies regions with microthromboemboli during primary angioplasty in acute coronary thrombosis. AU - Sakuma, Tadamichi. AU - Sklenar, Jiri. AU - Leong-Poi, Howard. AU - Goodman, Norman C.. AU - Glover, David K.. AU - Kaul, Sanjiv. PY - 2004/7/1. Y1 - 2004/7/1. N2 - Microthromboemboli (MTE) may contribute to the no-reflow phenomenon in acute myocardial infarction (AMI) either spontaneously or after primary percutaneous transluminal coronary angioplasty (PTCA). We hypothesized that myocardial MTE in acute coronary syndromes can be identified on imaging by in vivo 99mTc labeling of the coronary thrombus with a compound that binds to the glycoprotein IIb/IIIa present on activated platelets (DMP-444). Methods: Fifteen dogs underwent left anterior descending coronary artery (LAD) injury in to produce thrombus, whereas 5 control dogs had LAD ligation. Before recanalization, the risk area (RA) and myocardial blood flow (MBF) were measured, and in vivo thrombus ...
Plaque erosion is suspected in the presence of an acute luminal thrombus that is in direct contact with the underlying intima comprising smooth muscle cells and proteoglycan with an absence of endothelial lining (1). The erosive plaques are rich in versican, hyaluronan, and type III collagen, unlike rupture or stable plaques, which are rich in type I collagen (2). The erosion lesions are more often eccentric and infrequently calcified; they show minimal inflammation with a few or absent macrophages and T-lymphocytes (2). The media underneath plaque erosions are similar to plaques with mild stenosis, rich in smooth muscle cell actin, which is also highly expressed in intimal smooth muscle cells in erosions. Plaque erosions often show negative remodeling. It is likely that spasm may play an important role in plaque erosion.. Plaque erosion accounts for 25% to 35% of coronary thrombi in patients dying of acute myocardial infarction and/or sudden coronary death (1). Plaque erosions occur in ...
The Academic Research Consortium (ARC) divides stent thrombosis (ST) into early (within 30 days), late (30 days to 1 year), and very late (beyond 1 year). Intravascular imaging studies, to date mostly using intravascular ultrasound (IVUS), have provided clues with regard to the causes of ST-primarily by focusing on either early or very late ST, although each study usually includes a small number of patients with events between 30 days and 1 year. In this issue of JACC: Cardiovascular Interventions, the current study is similar in that 15 of 18 patients have very late ST with only 3 patients presenting earlier than 1 year (and those 3 at least 172 days) after implantation (1).. The distinction between patients with early versus very late ST is important, especially after drug-eluting stent (DES) implantation. Studies should not combine these 2 groups of patients, because their fundamental mechanisms seem to be different.. The IVUS-identified causes or predictors of early ST are mechanical and ...
The changes in the final ventricular complex, the T-wave, and in the S-T segment of the electrocardiogram in coronary thrombosis have been extensively studied, both experimentally and clinically, since the early works of Herrick,1 Smith,2 and Pardee.3 As a result, it has been generally accepted that characteristic changes do occur in the majority of the cases, following an attack of coronary thrombosis.. In contrast, the changes in the initial ventricular complex have, up to recent years, received much less attention. Smith2 and Wearn4 observed that in coronary thrombosis the initial ventricular complex may not rarely be of a very small ...
To the Editor:. There are questions regarding long-term safety of drug-eluting stents (DES), especially concern about an increased rate of late DES thrombosis compared with bare-metal stents. Numerous intravascular ultrasound (IVUS) studies have reported an increased frequency of late stent malapposition (LSM) in patients with DES (1-3), speculating that there may be a relationship between LSM and late stent thrombosis. The present study reports the long-term (,2 years) follow-up after the diagnosis of LSM was made using serial IVUS examination after DES implantation.. We previously reported 82 patients (85 lesions) with LSM from an overall cohort of 557 patients (705 native lesions) who underwent DES implantation (mean interval between baseline and follow-up IVUS of 6.1 ± 2.1 months). No intervention was performed in 542 patients (683 lesions) at 6-month follow-up (3). At least 2-year follow-up was available for all but 10 patients (12 lesions). Therefore, the present study reports 532 ...
Coronary thrombosis definition, a coronary occlusion in which there is blockage of a coronary arterial branch by a blood clot within the vessel, usually at a site narrowed by arteriosclerosis. See more.
Medical literature has recently focused on very late stent thrombosis (VLST) after drug-eluting stent implantation, while its mechanistic issue was not fully explored in the bare-metal stent (BMS) era. The first case is a 59-year-old man presenting with inferior non-ST-segment elevation myocardial infarction, 4 years after BMS implantation (NIR 3.5/18 mm, Boston Scientific, Galway, Ireland) for a chronic total occlusion lesion in the proximal right coronary artery. Coronary angiograms showed Thrombolysis In Myocardial Infarction (TIMI) flow grade 1 and filling defects in the BMS deployed previously, and massive red thrombi attaching to uncovered stent struts were found by angioscope (Fig. 1,Online Video 1). Thrombectomy and adjunctive balloon angioplasty were performed based on the angioscopic findings, and TIMI flow grade 3 was obtained. The second case is a 71-year-old man who was admitted for a diagnosis of inferior non-ST-segment elevation myocardial infarction 10 years after a treatment ...
The present study showed that the thrombi of ruptured plaques were more significantly rich in fibrin and that more tissue factor and CRP were expressed in ruptured than in eroded plaques.. Acute coronary thrombosis leading to acute myocardial infarction may arise from a difference in underlying plaque morphology, namely rupture and superficial erosion.2-6 In acute coronary death with coronary thrombosis, two necropsy studies have found plaque rupture in 75% of cases and that erosion accounted for the remainder.2,6 Kojima and colleagues5 found plaque rupture in 81% and erosion in 19% of Japanese patients who died of acute myocardial infarction.5 The findings of the present study agree with these previous results. In contrast, Farb and colleagues3 and Burke and associates4 have reported that 56% of such deaths are associated with plaque rupture and 44% with erosion. In addition, they found plaque erosion in 69% of women who died of sudden ischaemic heart disease.3,4 These reports emphasised a high ...
A number of risk factors for stent thrombosis have been identified by previous investigators. Persistent dissection, longer stent length, and final lumen diameter within the stent were identified as independent multivariable predictors of stent thrombosis in a meta-analysis of 6,186 patients enrolled in six major clinical trials of coronary stenting (17). Other studies have identified balloon size ≤2.5 mm, bail-out situations, unstable angina or acute MI (15), ejection fraction, use of a combination of different stents, postprocedural dissections, and slow flow (16)as predictive of stent thrombosis.. Multivariate analysis of correlates of stent thrombosis is difficult to perform in even a study as large as this because of the low incidence of the primary end point. A common method of avoiding over-fitting is bootstrap model selection. It involves creating random data sets from the patient population, selecting correlates with stepwise model selection for each bootstrap sample, and counting the ...
Background Clinical evidence suggests that intracoronary thrombus formation is associated with a high incidence of late restenosis after successful coronary intervention in patients with myocardial infarction. However, little is known about the mechanism by which intracoronary thrombi play pathological roles.. Methods and Results We analyzed the cellular constituents of 108 thrombi aspirated from coronary lesions with a thrombectomy device in 62 patients who underwent emergent coronary intervention for the treatment of acute (,24 hours) or recent (24∼72 hours) ST-segment-elevation myocardial infarction (44 male, 18 female, age 68.0±19.3 years). Immunohistological analysis of aspirated thrombotic materials revealed that the content of platelets, as determined by immunostaining for CD42a, had a negative correlation with the time after the onset of chest pain (correlation coefficient: −0.683, p,0.01). Immunofluorescent staining for CD34 and breast cancer resistant protein-1 (bcrp-1) detected ...
Percutaneous coronary intervention (PCI) and coronary stent insertion has become commonplace and is ubiquitous in the treatment of myocardial infarction. Use of dual antiplatelet therapy or "DAPT" (ASA plus clopidogrel, ASA plus prasugrel, ASA plus ticagrelor) is critical post PCI and coronary stent insertion to prevent stent thrombosis. The incidence of early stent thrombosis ranges around 1-2% while on DAPT while late stent thrombosis ranges from 0.2-0.6%.1 While the incidence may be low, acute stent thrombosis often presents as a STEMI and is associated with mortality rates of 20-45%. While several factors influences the rates of stent thrombosis, the most common cause of acute stent thrombosis is nonadherence to DAPT.2. ...
Another name for Coronary Thrombosis is Heart Attack. The treatment of a heart attack focuses on reducing pain, improving blood flow to the heart muscle ...
Coronary thrombi in patients who die suddenly are more likely to display signs of healing if they are caused by a plaque erosion rather than a rupture, researchers found.
The pathophysiological model for the occurrence of STEMI describes sudden vessel closure, mostly due to plaque rupture or erosion and subsequent intracoronary occlusive thrombosis at the onset of symptoms.3 Plaque disruption results in exposure of the lipid-rich core of the plaque to the bloodstream, which causes activation and aggregation of platelets. As a result, a luminal thrombus occurs, which prevents normal blood supply to the myocardium. This explains why in many patients with acute transmural myocardial infarction, a platelet-rich, fresh thrombus can be found.12-15 The aspiration of thrombi in 95% of patients in general and fresh thrombi in particular in patients with STEMI in the present study confirms these perspectives and other studies with regard to the pathogenesis of this event. The fact that fresh thrombus could not be identified in all patients may be explained in part by disintegration of the very fragile fresh material by passage through the catheter or in the collection ...
Coronary thrombus in patients undergoing primary PCI for STEMI: Prognostic significance and management.: Acute ST-elevation myocardial infarction (STEMI) usuall
Coronary thrombosis is now widely recognised as a major cause of sudden cardiac death, acute myocardial infarction, and unstable angina pectoris. Inflammation is an important component of the atherosclerotic lesion. In this review we will discuss inflammatory mechanisms in relation to atherosclerosis and clinical coronary thrombosis.. The "response to injury" hypothesis postulates that endothelial dysfunction represents the initial step of atherogenesis and can be induced by haemodynamic forces, by a variety of vasoactive substances, by mediators from blood cells, and directly from risk factors for atherosclerosis.1 Upon activation, endothelial cells express various cellular adhesion molecules, cytokines, chemokines, and growth factors. Focal arterial inflammatory activity is one of the most prominent characteristics of the atherosclerotic process.2,3 Inflammation is also implicated in the pathogenesis of acute syndromes, as suggested by histological findings in unstable coronary plaques,4-6 ...
This is a widget area - If you go to "Appearance" in your WP-Admin you can change the content of this box in "Widgets", or you can remove this box completely under "Theme Options" ...
Your initially span I actually exploration information as a result of Beef Cape, I dropped for want immediately. Just about anything Muhammad suggested as well as accomplish suffered very little to try and do through christian opinions, as well as church property to the difficulty, though to do national healthcare benefits during his hopes to outweigh the globe. In these days, preferably in the regular nine generate ranges the user gets a different a particular, so you have acquired a possibility to wager on the subject of 10 with them. So im not signifying to make sure you end up being arch but I encounter damaging to happened honestly to recognize the God involved with prefer so you cant seem to be to build around ones own mental health stress. Actually many instances pharaoh appears to have been prepared enable His or her individuals proceed and usually knowledgeable the particular Hebrews for you to piss incorrect (Exodus 9: 28; 10: 10; 10: 24; 12: 31-33), but simply hardly any, Our god ...
This is a widget area - If you go to "Appearance" in your WP-Admin you can change the content of this box in "Widgets", or you can remove this box completely under "Theme Options" ...
trigger the formation of a clot causing a coronary thrombosis. This stops the flow of blood through the vessel and the capillary network it supplies causing a heart attack. The portion of the heart muscle deprived of oxygen dies quickly of oxygen starvation. If the area is not too large, the undamaged part of the heart can, in time, compensate for the damage. Coronary bypass surgery uses segments of leg veins to bypass the clogged portions of the coronary arteries. ...
Project plan. Modeling rat bloodstream using fluorescence imaging data. Alander et al. (2012). The Research Project. Rats with artificial coronary thrombosis Chest blood vessel to heart muscle Replace bypass for people with bad coronary vessels ?. Team. Slideshow 6945525 by...
Stent thrombosis (ST) is an acute thrombotic occlusion in the stented segment of a coronary artery. It is a serious complication that frequently presents as an acute myocardial infarction and/or sudden death. The most recently accepted definition established by the Academic Research Consortium classifies ST as: early (occurring within 30 days), late (30 days to 1 year) or very late (after 1 year). Very late ST has been reported following drug-eluting stent implantation with rates up to 0.6% per year. However, very late ST is unusual after bare-metal stent (BMS) implantation. Here we report a case of patient presenting with ST-elevation myocardial infarction due to very late ST occurring 2 years after BMS implantation. Keywords: Stent thrombosis, Percutaneous coronary intervention, Bare metal stent, Drug eluting stent
Case Reports in Critical Care is a peer-reviewed, Open Access journal that publishes case reports in all areas of critical care medicine.
For the past 15 years evidence has stacked up showing patients with acute coronary thrombosis improve their survival chances by 50-82
coronary (artery) occlusion. coronary (artery) rupture. cardiac infarction. infarction of heart, myocardium, or ventricle. rupture of heart, myocardium, or ventricle. acute myocardial infarction occurring within four weeks (28 days) of a previous acute myocardial infarction, regardless of site. subsequent type 1 myocardial infarction. reinfarction of myocardium. coronary (artery) embolism. coronary (artery) thrombosis. recurrent myocardial infarction. ...
Current trial protocol definitions of stent thrombosis. CEC process for adjudication of definite/confirmed ST has been the same for all major trials of DES Acute myocardial ischemia (ECG major ST abnormality or any biomarker elevation) ANDAngiographic or autopsy evidence of stent occlusion or thrombusAbsence of intervening TLRPossible/presumed STMI in target vessel territory without angiographic evidence of thrombus or other culpritVariably reported among different devices and within studi31646 Slideshow 1281571 by mardi
Almost all heart attacks occur when a blood clot suddenly and completely blocks a coronary artery. This condition is called a coronary thrombosis, or simply a coronary. The part of the heart muscle nourished by the blocked artery becomes damaged by lack of oxygen.
s body exhumed in order to prove her case. We were told that my sister had died of coronary artery thrombosis, but she didnt have a history of heart disease, she said this week. There was no trace of alcohol or barbiturates in her system, but there was this brown cereal-type substance which was never identified. I believe she was killed because someone wanted to silence her. But who? Maxine admits that she has privately confronted the man she suspects of being responsible for her sisters death. ...
Wells Carl CLINGMAN - Yavapai County Arizona - b. March 6, 1899, Ft. Worth, Tx. d. Jan. 27, 1955, Cottonwood, Az. COD: Coronary thrombosis h/o Hattie Louise Clingman s/o Charles Mmagne & Atlanta E. (Stevens) Clingman Occ: Farm laborer Wagoner, Med. Dept. - WW I Enlisted: June 4, 1917 Discharged: Aug. 21, 1919 Note: Resided in Az. 50 years. Site # A/166 Westcott Funeral Home, Cottonwood, Az. Burial: Jan. 20, 1955 Az. death records /Military records Picture taken by Kelley Townsend
Alma Mae ORTWINE - Yavapai County Arizona - Alta M.(Troutwine) Ortwine b. Feb. 2, 1900, Pidgion, Mich. d. July 9, 1964, Prescott, Az. COD: Coronary thrombosis w/o Frank Simon Ortwine d/o Adolph & Amelia M. (Wagoner) Troutman Site # S/010/H Hampton Funeral Home, Prescott, Az. Buried July 13, 1964
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
DESs have dramatically decreased the need for coronary artery bypass graft (CABG) surgery and repeated PCI. However, late stent thrombosis is a small but important risk with DESs because it is commonly associated with sudden death or acute MI. The clinical occurrence of stent thrombosis after stent implantation can be defined as acute (, 24 h), subacute (1 to 30 d), late (30 d to 1 y), or very late (, 1 y). The clinical diagnosis of stent thrombosis can be defined as "definite" if proven angiographically or pathologically, "probable" if an MI occurs in the distribution of the stented artery, or "possible" if death is unexplained (1). Risk for subacute stent thrombosis is about 1% for both DESs and BMSs, but risk for very late stent thrombosis continues for at least 4 years with DESs at a rate of 2 to 4 events/1000 patients per year (1−3). The presumed cause is delayed or incomplete endothelialization of the stent struts. The unanswered question is whether the decrease in risk for death and MI ...
Most physicians believe that acute coronary syndromes (ACS) are due to coronary artery thrombosis resulting from plaque rupture of a metabolically active inflamed lesion characterized by a thin fibrous cap (thin-cap fibroatheroma [TCFA]), overlying a large necrotic core containing rich concentrations of cholesterol, cholesterol esters, and senescent macrophages (1). Such lesions also demonstrate spotty calcification and neovascularization arising from the vasa vasorum with plaque hemorrhage. Indeed, the chemical structure and morphology of the TCFA is so distinctive that numerous invasive and noninvasive imaging modalities have been developed to search for the mischievous TCFA prior to its becoming unstable, to improve prognostic discrimination and perhaps guide systemic or focal therapies.. However, although pathologic studies have demonstrated that the majority of thrombotic lesions responsible for acute myocardial infarction (AMI) and sudden cardiac death have a ruptured fibrous cap (RFC) ...
Lines of Zahn are a characteristic of thrombi that appear particularly when formed in the heart or aorta. They have visible and microscopic alternating layers (laminations) of platelets mixed with fibrin, which appear lighter and darker layers of red blood cells. Their presence implies thrombosis at a site of rapid blood flow that happened before death. In veins or smaller arteries, where flow is not as constant, they are less apparent. They are named after German-Swiss pathologist Friedrich Wilhelm Zahn. "Atherosclerosis". Lee R, Adlam D, Clelland CA, Channon KM (2012). "Lines of Zahn in coronary artery thrombus". Eur Heart J. 33 (9): 1039. doi:10.1093/eurheartj/ehs028. PMID 22345124. Stegman, JK, ed. (2006), Stedmans Medical Dictionary (28th ed.), Baltimore, MD: Lippincott, Williams, & Wilkins Kumar, V. et al. (2005). Hemodynamic Disorders, Thromboembolic Disease, and Shock. Robbins and Cotran Pathologic Basis of Disease. 7th edition. Elsevier Saunders: Pennsylvania. Simon S. Cross (ed.). ...
Novel nanostructured biomaterials: implications for coronary stent thrombosis Varvara Karagkiozaki,1,2 Panagiotis G Karagiannidis,1 Nikolaos Kalfagiannis,1 Paraskevi Kavatzikidou,1 Panagiotis Patsalas,3 Despoina Georgiou,1 Stergios Logothetidis11Lab for Thin Films – Nanosystems and Nanometrology (LTFN), Physics Department, Aristotle University of Thessaloniki, Thessaloniki, 2AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, 3Department of Materials Science and Engineering, University of Ioannina, Ioannina, Epirus, GreeceBackground: Nanomedicine has the potential to revolutionize medicine and help clinicians to treat cardiovascular disease through the improvement of stents. Advanced nanomaterials and tools for monitoring cell–material interactions will aid in inhibiting stent thrombosis. Although titanium boron nitride (TiBN), titanium diboride, and carbon nanotube (CNT) thin films are emerging materials in the biomaterial field, the effect of their surface properties on
To explore effective and convenient rescue therapy options for coronary artery aneurysms (CAA) with thrombosis in Kawasaki disease (KD). A total of
This study reports a significantly lower risk of ST during the first year after PCI with both n-DES and o-DES compared with BMS, but a higher risk of very late ST up to 3 years in the o-DES group compared with the BMS group; and a similar risk of very late ST in the n-DES and BMS groups. Although BMS have been proven to be safe in STEMI patients and the improvements of the new stent platforms have reduced restenosis rates, DES are superior in terms of a decrease in restenosis occurrence. This study suggests that n-DES are associated with a low risk of ST even on long-term follow-up and may be the preferred stent type in STEMI patients compared to BMS and o-DES. ...
The study by den Heijer and colleagues is of interest to both interventional cardiologists and internists. The availability of low-profile, flexible, and steerable angioscopic systems has allowed the routine percutaneous application of this technology. Interpretable images can now be obtained in most patients having interventional procedures, although the technique still has important limitations. Problems remain with aiming the angioscope, and a clear imaging field cannot always be obtained. The widespread availability of second-generation interventional technologies, including stents, atherectomy catheters, and local drug delivery systems, give the interventionist a choice of therapies. Precise knowledge of coronary morphology may have an important effect on the decision of which technique to use to treat a given lesion. The study by den Heijer and colleagues suggests that, in a few patients, the angioscopic information was useful to the clinician. These results, however, cannot be ...
Myocardial infarction. Theres a mouthful. Its a tongue-twiser, isnt it? And it sounds serious.. Well, it is.. Myocardial infarction is medical language for a heart attack. It means the death of tissue (an infarct) in the muscular wall of the heart (the myocardium).. Heart attack is known by several names. coronary thrombosis is a heart attack caused by a clot in the coronary arteries. Sometimes, it is caused by snoring. Coronary occlusion is a blocked artery that could have a number of causes. Myocardial infarction refers to the end result-the damage or death of a part of the heart muscle.. The heart never stops working. In contrast to the muscles in our arms and legs, the heart muscle never rests, although it does slow down when we sleep.. to do its important job of keeping us alive, the heart must have a regular and adequate supply of oxygen and nutrients for energy. For this reason, the heart receives its own supply of oxygen-rich blood by way of the coronary arteries. The sole purpose of ...
Shah, N., Garg, J., Agarwal, V., Mehta, K., Jacobs, L., Patel, N., Freudenberger, R. Stent Thrombosis is Not Increased in Cardiac Arrest Patients Undergoing Therapeutic Hypothermia: An Analysis of 15,079 Procedures. Poster presented at: American College of Cardiology, San Diego, CA.. ...
Review of the recent literature reveals little dealing with the effects of large doses of quinidine on ventricular tachycardia. No series comparable in size to this one has been noted within the past 15 years. McMillan1 recently reported two cases following coronary thrombosis treated successfully with quinidine. Reich2 reported a cure with a total of 185 grains given in a period of two and a half days, a dosage believed by him and also by Levine3 and Gold4 to be the largest dose given in a period of 60 hours. Some of the cases in this series had quinidine in ...
Feng QZ, Wang SW, Zhao YS, Zheng XQ.Subacute stent thrombosis happening at discharge. International Journal of Cardiology 119: E59-E62, No. 2, 10 Jun 2007 - ChinaGoogle Scholar ...
Thrombosis yw tolchenni gwaed a all fod yn farwol syn ffurfio yn y rhedweli (thrombosis rhedwelïol) neu yn y wythïen (thrombosis gwythiennol). Ar ôl i dolchen ffurfio, gall arafu neu rwystro llif gwaed a hyd yn oed gwahanu ei hun a theithio i organ. Gelwir tolchen syn teithio ir system gylchrediad yn emboledd.. Gan amlaf, mae modd atal thrombosis ac maen batholeg o drawiadau ar y galon, strociau thrombo-embolig a thrombo-emboledd gwythiennol (VTE) - sef y tri phrif achos o farwolaethau cardiofasgwlaidd.. Maer Bartneriaeth Effeithiau Gofal Iechyd Cyngor Ymchwil Peirianneg ar Gwyddorau Ffisegol ar Ddiagnosteg a Rheoli Tolchennu Gwaed a arweinir gan Brifysgol Abertawe yn cynnwys athrawon, darlithwyr, ymchwilwyr ôl-ddoethurol, a myfyrwyr o Goleg Peirianneg ac Ysgol Feddygaeth y Brifysgol yn ogystal â phartneriaid ym maes diwydiant a phartneriaid o dramor. Bydd y Bartneriaeth yn cynnal digwyddiad codi arian a chodi ymwybyddiaeth ar Gampws y Bae y Brifysgol ddydd Iau 13 Hydref lle y byddant ...
Thrombosis: Thrombosis,, formation of a blood clot in the heart or in a blood vessel. Factors that play a role in the formation of clots (thrombi) include injury to a blood vessel and
Although almost 10% of middle-aged persons who have major operations afterward develop thrombosis* a serious disease caused by clots which jam the blood vessels they dont need to....
We provide a state-of-the-art intracoronary imaging system that helps you optimize the treatment of patients and master complex lesions. Our optics-based imagin
TY - JOUR. T1 - Drug-eluting stent thrombosis in routine clinical practice two-year outcomes and predictors from the Taxus arrive registries. AU - Lasala, John M.. AU - Cox, David A.. AU - Dobies, David. AU - Baran, Kenneth. AU - Bachinsky, William B.. AU - Rogers, Edwin W.. AU - Breall, Jeffrey A.. AU - Lewis, David H.. AU - Song, Aijun. AU - Starzyk, Ruth M.. AU - Mascioli, Stephen R.. AU - Dawkins, Keith D.. AU - Baim, Donald S.. PY - 2009/8. Y1 - 2009/8. N2 - Background-Stent thrombosis (ST) is an uncommon but serious complication of drug-eluting and bare metal stents. To assess drug-eluting stent ST in contemporary practice, we analyzed 2-year data from the 7492-patient ARRIVE registry. Methods and Results-Patients were enrolled at the initiation of percutaneous coronary intervention with no inclusion/ exclusion criteria beyond use of the paclitaxel-eluting TAXUS stent. Two-year follow-up was 94% with independent adjudication of major cardiac events. A second, autonomous committee ...
A case of successful reperfusion through a combination of intracoronary thrombolysis and aspiration thrombectomy in ST-segment elevation myocardial infarction associated with an ectatic coronary artery. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Dual antiplatelet therapy is established for prevention of stent thrombosis in cardiac patients, and widely utilized in neurointerventional stent cases. Aspirin and clopidogrel are typically synergistic. We present a case of clopidogrel resistance due to genetic polymorphism resulting in acute stent thrombosis during elective stent-assisted coiling, with novel use of prasugrel as an alternative platelet inhibitor in the neurovascular setting. ...
Intracoronary thrombosis and the attendant risk of myocardial ischemia or infarction may occur soon after percutaneous coronary intervention with stent implantation. Trauma to the coronary endothelium (with the exposure of tissue factors to blood) an
The data on increased stent thrombosis rates in bare metal stents may be one of the surprises of the DAPT trial because, in 2006, when the first concerns over increased stent thrombosis rates in DES surfaced, a large number of clinicians reverted to the earlier bare metal devices. Dr. Kereiakes will be presenting a more detailed analysis of these data in a Tuesday presentation, but this observation mirrors some of the findings in the ZEUS study, reported on previously by Angioplasty.Org.. Although the DAPT trial seems to give a green light to extended duration of DAPT therapy, many clinicians have stated that one size fits all medicine cannot be invoked in these situations, that a more individualized approach is required. Some patients are less at risk for stent thrombosis, or they may need surgery requiring cessation of DAPT therapy. Recent studies, with newer second generation stents, have shown no adverse effects from early interruption of DAPT therapy.. In fact, one very important set of ...
After a year of follow-up, patients with STEMI who received thrombus aspiration during PCI had similar results in the primary outcome of cardiovascular death, recurrent MI, cardiogenic shock or class IV heart failure compared with patients undergoing PCI alone, according to a prospective, randomized trial.
n. the dissolution of a blood clot (thrombus) by the infusion of a fibrinolytic agent into the blood. It may be used in the treatment of phlebothrombosis, pulmonary embolism, and coronary thrombosis. See also tissue-type plasminogen activator. ...
Synonyms for Arteriosclerotic heart disease in Free Thesaurus. Antonyms for Arteriosclerotic heart disease. 5 words related to coronary heart disease: coronary occlusion, coronary, coronary thrombosis, cardiopathy, heart disease. What are synonyms for Arteriosclerotic heart disease?
Objectives: To present the possibility of acute arterial and venous thrombosis. Materials and methods: Report of a patient presenting with acute dyspnoea and chest pain. Results: Using a combined medical team and imaging studies, pulmonary embolism and acute arterial thrombosis were diagnosed. The patient was treated medically and surgically. Conclusion: Physicians should be aware of the possibility of combined thrombosis and the diagnosis and management of the condition.. ...
Akhilesh Sista (New York, USA) talks about the results of the EXTRACT-PE study, presented in a late-breaking clinical trial session at VIVA 2019.
Dr. Cameron Wright presents Bleeding and Thrombosis After PTE, recorded live at the UC San Diego Health Sulpizio Cardiovascular Center National Proceedings: CTEPH 2017., TV Network
Dr. Cameron Wright presents Bleeding and Thrombosis After PTE, recorded live at the UC San Diego Health Sulpizio Cardiovascular Center National Proceedings: CTEPH 2017., TV Network
Thrombosis is the process of a blood clot, also known as a thrombus, forming in a blood vessel. This clot can block or obstruct blood flow in the affected area, as well as cause serious complications if the clot moves to a crucial part of the circulatory system, such as the brain or the lungs.
BPT) - 世界中の4人に1人が、血栓症または血管内に形成される血栓関連の病状により死亡しています。米国と欧州では毎年、血栓症に関連する事象による死亡は、乳がん、HIV、自動車事故を合わせた死亡件数よりも多くなっています。しかし、血栓について、またその由来が驚くべきことに病院であるという事実を知る人はほとんどいません。 有害な血栓は通常、脚、鼠蹊部(そけいぶ)、または腕の深部静脈に形成されます(深部静脈血栓症、DVT)。その後、DVTは循環器系を移動し、肺に留まる可能性があります(肺塞栓症、PE)。DVTとPEを合わせて静脈血栓塞栓症(VTE)と呼ばれます。これは死に至るおそれがあることから危険です。 ...
MAIA, Felipe et al. Comparison of vascular response to different doses and patterns of elution of sirolimus-eluting stents using coronary intravascular ultrasound. Rev. Bras. Cardiol. Invasiva [online]. 2009, vol.17, n.3, pp.320-326. ISSN 2179-8397. http://dx.doi.org/10.1590/S2179-83972009000300008.. BACKGROUND: Positive vascular remodeling after percutaneous coronary intervention (PCI) using drug-eluting stents may be associated to a high dose of an anti-proliferative agent and/or local toxicity of the synthetic polymer. This may lead to late incomplete aposition of the struts, acting as a late/very late thrombosis risk factor. Our objective was to assess the vascular response secondary to sirolimus drug-eluting stent implantation using different doses and patterns of elution by means of serial intravascular ultrasound (IVUS) analysis. METHOD: We assessed 50 patients with low to moderate cardiovascular risk divided into 3 groups according to the sirolimus dose and pattern of elution: group 1, ...
Whereas thrombus aspiration in patients with ST-elevation myocardial infarction (STEMI) is recommended by current guidelines, there are insufficient data to unequivocally support thrombectomy in patients with non-STEMI (NSTEMI). The Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI) trial is a 400 patient, prospective, controlled, multicenter, randomized, open-label trial. The hypothesis is that under the background of early revascularization, adjunctive thrombectomy in comparison to conventional percutaneous coronary intervention (PCI) alone leads to less microvascular obstruction (MO) assessed by cardiac magnetic resonance imaging (CMR) in patients with NSTEMI. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary endpoint is the extent of MO assessed by CMR. Secondary endpoints include infarct size and myocardial salvage assessed by CMR, enzymatic infarct size as well as angiographic ...
Whereas thrombus aspiration in patients with ST-elevation myocardial infarction (STEMI) is recommended by current guidelines, there are insufficient data to unequivocally support thrombectomy in patients with non-STEMI (NSTEMI). The Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI) trial is a 400 patient, prospective, controlled, multicenter, randomized, open-label trial. The hypothesis is that under the background of early revascularization, adjunctive thrombectomy in comparison to conventional percutaneous coronary intervention (PCI) alone leads to less microvascular obstruction (MO) assessed by cardiac magnetic resonance imaging (CMR) in patients with NSTEMI. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary endpoint is the extent of MO assessed by CMR. Secondary endpoints include infarct size and myocardial salvage assessed by CMR, enzymatic infarct size as well as angiographic ...
Background The TASTE trial did not demonstrate clinical benefit of thrombus aspiration (TA). High-risk patients might benefit from TA. Methods The TASTE trial was a multicenter, randomized, controlled, open-label trial obtaining end points from national registries. Patients (n = 7,244) with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) were randomly assigned 1: 1 to TA and PCI or to PCI alone. We assessed the 1-year clinical effect of TA in a subgroup with potentially large anterior STEMI: mid or proximal left anterior descending coronary artery infarct lesion, thrombolysis in myocardial infarction 0 to 2 flow, and symptom onset to PCI time = 5 hours. In this substudy, patient eligibility criteria corresponded to that of the INFUSE-AMI study. Results In total, 1,826 patients fulfilled inclusion criteria. All-cause mortality at 1 year of patients randomized to TA did not differ from those randomized to PCI only (hazard ratio [HR] 1.05, 95% ...
Background. Commonly tested Loss-of-function (LOF) alleles in CYP2C19 are present in 30-40% of patients who experience stent thrombosis. The objective of this study was to identify novel genetic variants in CYP2C19 gene associated with stent thrombosis.. Methods. We included 70 patients with definite stent thrombosis while on clopidogrel who had stored DNA samples in our institutional (n=12) or PLATO trial (n=70) biorepository. Cases were matched 1:1 with controls for age, race, sex, diabetes, type of stent, and presentation. All controls were on clopidogrel and free of recurrent events. Clinical Pharmacogenetics (PGx) Implementation Consortium (CPIC) guidelines were used to determine the list of known PGx variants and dbSNP version 142 was used to assess novel variants. Whole exome sequencing was performed using the protocol for Agilents SureSelect Human All Exon v5 + UTRs 75 MB kit and additional custom primers were designed to cover the entire CYP2C19 gene.. Results. Mean age was 63 ± 12 ...
THERAPY sought to establish the benefit of aspiration thrombectomy in conjunction with intravenous-alteplase when compared with intravenous-alteplase alone in patients with a large anterior circulation proximal clot burden (≥8 mm), but it was halted early based on external evidence demonstrating the efficacy of thrombectomy.6-10 Consequently, THERAPY was not powered to meet its predefined end points. Although the primary end point was not achieved, prespecified secondary end points suggest potential for benefit for aspiration thrombectomy (Figure 2A). In addition, although nonsignificant, the magnitude of potential treatment effect observed for the primary outcome measure is consistent with those of the recent positive thrombectomy trials (Figure 2B). Finally, similar to ESCAPE (The Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times) and EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological ...
Acute Ischemic stroke (AIS) remains a leading cause of adult disability, cognitive impairment and mortality worldwide despite the development of revascularization therapies (intravenous Tissue Plasminogen Activator (t-PA) and endovascular therapy). Thrombosis resistance after IV t-PA therapy is frequent especially in case of AIS with proximal occlusion. In recent years, neutrophil extracellular traps (NETs) have been identified as major triggers and structural factors of various forms of thrombosis. NETs are extracellular webs primarily composed of DNA from neutrophils. A recent study shows that the NETs burden in coronary thrombi is positively correlated with the infarct size and negatively correlated with electrocardiogram (ST-segment) resolution. This later study revealed that in vitro addition of DNase I accelerated the t-PA-induced thrombolysis of coronary thrombi. NETs could, in consequence, be promising targets for improved thrombolysis in AIS ...
Individual components of the primary outcome also were similar between the two stents. Cardiac death was 1.2% with BuMA vs. 1.3% with Excel (P = .86), target-vessel MI was 4.3% vs. 4.9%, respectively (P = .49) and ischemia-driven TLR was 1.9% vs. 1.2%, respectively (P = .18). A patient-oriented composite endpoint of death, MI or any revascularization at 1 year yielded equivalent results for both devices.. Stent thrombosis differed. The BuMA SES, however, was associated with a lower rate of definite or probable stent thrombosis compared with Excel: 0.5% vs. 1.3% (P = .047). Given that the cumulative incidence of stent thrombosis was low overall, Xu called for caution, noting that PANDA III "was not powered adequately to evaluate low-frequency safety endpoints such as stent thrombosis." Nonetheless, he concluded that the decreased stent thrombosis for BuMA seen here is consistent with the BuMA-OCT trial, which showed better strut coverage at 3 months with BuMA vs Excel.. "Its fascinating" that ...
Three cases of definite stent thrombosis (2 in the mesh stent group, 1 in the BMS group) occurred, with none resulting in death. There were no differences between the groups in infarct size.. Interventionalists Must Balance Pros and Cons. The MGuard is specifically designed f or thrombus-containing lesions. Previously, the MASTER trial, presented at Transcatheter Cardiovascular Therapeutics in October 2012 and simultaneously published in the Journal of the American College of Cardiology, demonstrated an increased rate of complete ST-segment resolution with MGuard compared with conventional BMS and DES. In an email with TCTMD, Dr. Fernández-Cisnal noted that while the stent has been reported to be a useful device for reducing distal microembolization in STEMI patients, as measured by myocardial blush grade and ST-segment resolution, no differences have been observed in clinical endpoints. "Higher, but nonsignificant, rates of TLR and TVR were observed in some studies [that compared the MGuard] ...
To the Editor: When is atherosclerosis not atherosclerosis? In the last decade, there have been 2 revolutions in the study of atherosclerosis. On the one hand, a more sophisticated appreciation of the relationship between the morphology and fate of human atherosclerotic plaques and clinical outcomes has been developed. On the other hand, the blossoming of mouse genetics has allowed us the possibility of exploring prospectively the mechanisms that lead to various types of atherosclerotic lesions. These advances, in the view of the author, should compel us as experimentalists, mainly using murine models, to fashion a more nuanced view and description of experimental atherosclerosis.. The last issue of Arteriosclerosis, Thrombosis, and Vascular Biology contained a review on a comprehensive morphologic classification scheme for atherosclerotic lesions, which was derived by studies of lesions from autopsy examinations of sudden coronary deaths.1 There was also a commentary by Dr H. Stary2 updating ...
A free platform for explaining your research in plain language, and managing how you communicate around it - so you can understand how best to increase its impact.
T3 were mainly composed by platelets and fibrin(ogen), while T6 were characterized by reduced platelet content, and increased leukocyte infiltration with appearance of undifferentiated progenitor cells. Differences between T3 and T6 were found in the cell cytoskeleton-associated proteome (beta-actin and tropomyosin 3 and 4). Using discovery proteomics, Pfn-1 was identified in the coronary thrombi at higher levels in T3 compared to T6. Plasma Pfn-1 levels were low in T3 patients, but increased in both coronary and peripheral circulation in T6 patients indicating release. In vitro platelet aggregation studies showed that platelets secrete Pfn-1 upon complete activation.. ...
Magnesium deficiency appears to have caused eight million sudden coronary deaths in America during the period 1940-1994.[1] - Paul Mason. Paul Mason, famously known as the magnesium librarian, wrote, "For decades, the evidence has been overwhelming that Americans are very deficient in Mg, as evidenced by the 23% shortfall from the RDI, yet the FDA and DOJ have covered up their blunder, getting a Federal lawsuit dismissed before the evidence could be shown, and keeping silent about the millions of deaths indicated by over 50 epidemiological studies from nine countries. Recent studies clearly confirm that water-borne Mg is far, far better in preventing cardiovascular pathologies than food-borne Mg." Mason is the owner of a water mine that has the highest levels of magnesium and bicarbonate in the world!. In a study of postoperative ICU patients,[2] B. Chernow et al. found that the death rate was reduced from 41% to 13% for patients without hypomagnesemia (low magnesium levels). Other ...
Hyperattenuating signs are observed on unenhanced CT scans when an acute thrombus has formed in a blood vessel. It can be seen in various vascular diseases, including cerebral infarction; pulmonary thromboembolism; aortic dissection with a thrombosed false lumen; deep venous thrombosis; and, of course, CVST.8⇓-10 The increase in attenuation is caused by clot retraction, eliminating water and thereby raising the concentrations of red blood cells and hemoglobin. This mechanism results in increased attenuation of the thrombus to 60-90 HU. As time passes, the thrombus ages and is rechanneled so that the red blood cells and hemoglobin are degraded. Subsequently, the attenuation gradually decreases for approximately 7-14 days, at which point the thrombi cannot be differentiated from normal blood or may even appear hypoattenuating relative to blood.11. Hyperattenuating signs can serve as unique findings indicating an acute stage, at a time when treatment is most likely to be effective and to have a ...
Development of drugs for the treatment of congestive heart failure and cardiac oedema, Development of newer compounds from indigenous sources for the therapy of cardiac arrhythmias, Development of new complex coumarins for coronary thrombosis, related ...
Although the increased use of balloon expandable stents is a valuable contribution for diminishing the restenosis rate after PTCA 3, a number of papers reporting several severe complications have been published. The complications can be related to the site of percutaneous insertion (15% of all cases, 50% of which need surgical treatment 3,4 ) or the site of the coronary stent deployment, such as subacute stent thrombosis ( 3-5% in elective and 10-20% in emergency cases 4). In our case two complications were described: a peripheral one, a pseudoaneurysm, and a coronary one, an unsuccessful deployment of a balloon extended stent. The use of stents for lesions located in the proximal third of the LAD is a routine procedure. We also decided to use a stent in order to reduce the risk of restenosis. This type of stent is advanced across the lesion without a protective sheath. After placing the stent in the correct position, the balloon was expanded and unsuccessfully deployed, due to the fact that it ...
Fibrinolysis is the physiological breakdown of blood clots by enzymes such as plasmin.. Organisation: following the thrombotic event, residual vascular thrombus will be re-organised histologically with several possible outcomes. For an occlusive thrombus (defined as thrombosis within a small vessel that leads to complete occlusion), wound healing will reorganise the occlusive thrombus into collagenous scar tissue, where the scar tissue will either permanently obstruct the vessel, or contract down with myofibroblastic activity to unblock the lumen. For a mural thrombus (defined as a thrombus in a large vessel that restricts the blood flow but does not occlude completely), histological reorganisation of the thrombus does not occur via the classic wound healing mechanism. Instead, the platelet-derived growth factor degranulated by the clotted platelets will attract a layer of smooth muscle cells to cover the clot, and this layer of mural smooth muscle will be vascularised by the blood inside the ...
Doppler ultrasonography of the affected extremity with compression should be performed at diagnosis and then used in follow-up to determine resolution of an acute thrombus. Venography or MR angiograph... more
Yetino, M., Ozeke, O., Deveci, B., Timur Selcuk, M. and Aras, D. (2006) Multichamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy. The International Journal of Cardiovascular Imaging, 22, 59-61.
Stents have emerged as one of the major therapeutic tools for percutaneous intracoronary revascularization procedures. In fact, a stent is implanted in at least 30% of lesions attempted. Their clinical impact is huge because stenting has produced a decrease int the need for emergency surgery to 0.5%, with an incidence of acute myocardial infarction related to angioplasty of 2% and a death rate of , 1% despite unfavourable clinical and anatomical conditions treated. The initial price of stenting was a high frequency of subacute stent thrombosis and peripheral vascular complications, which has been solved ...
Arterial thrombosis is much less common than venous thrombosis, although it poses similar risks. The veins are responsible for taking blood and oxygen to different sections of the body. The blood is normally subject to higher pressure when it is travelling in the veins and may be moving more quickly. It is therefore less likely to clot in the arteries. Whereas venous thromboses normally lead to swelling and fluid congestion in an area, arterial thrombosis can lead to body tissue becoming starved of blood and oxygen. This can eventually lead to necrosis of the tissue. A thrombosis or embolism in the coronary artery can cause a heart attack. If blood supply to the brain is disrupted, the patient may suffer a stroke. ...
... Whittet, Sally; Hunt, Beverley // Pulse;8/20/2005, Vol. 65 Issue 33, p32 Presents the interview with Beverly Hunt, consultant hematologist and founder member of the thrombosis charity Lifeblood, about risks and causes of thrombosis. Symptoms and signs of thrombosis; Effectiveness of thromboprophylaxis in treating thrombosis; Risk factors of thrombosis. ...
Terumo has received the CE mark for its Ultimaster Tansei drug-eluting stent. Building on the Ultimaster stent, a press release reports, the Ultimaster Tansei features optimised technology that will benefit clinicians and their patients worldwide.
Thrombosis is the name given to the formation of blood clots in an area where clotting is not a medical necessity. When the body is injured in any way, the blood may need to clot at the site of the wound to help to prevent blood loss and promote healing. Platelets and Fibrin in the blood can bond together to produce a clot which protects the affected area. However, clots can sometimes form within blood vessels when they are not medically required. This normally happens because of a change in the speed of the blood flow or the core content of the blood.. Thrombosis can affect the flow of the blood around the body. Clots can partially or fully block a blood vessel, meaning that blood cannot circulate in the normal way. This is referred to as an embolism. Unexplained pain, heat or swelling in one area of the leg may suggest deep vein thrombosis.. Thrombosis is more likely to occur in people who are unable to move freely, for whatever reason; including those maintaining a sedentary lifestyle, ...
As part of a weeks long activities, Thrombosis UK will be holding FREE educational events in Belfast, Cardiff, Edinburgh and London. Each meeting will look at, early identification, assessment and management of thrombosis; consider thrombosis in high risk and specific groups, therapy options and safe management and also look at the psychological effect of thrombosis on patients.. Further information and to reserve your place visit www.thrombosisuk.org or email [email protected] Healthcare Conferences UK will be running ...
WARNING OF A SYNDROME OF STUNNING MYOCARDIUM AT INTRACORONARY THROMBOLYSIS WITH THE HELP OF THE DONOR OF NO-GROUPS SODIUM NITROPRUSSIDUM IN BUCCAL DRUG FORM IN THE PATIENTS WITH AN ACUTE CORONARY ...
(MedPage Today) -- Higher risk of stent thrombosis and MI under investigation via FDA Issues Warning for Absorb Stent by from Blogger http://ift.tt/2mGJntsvia https://www.youtube.com/channel/UC6RqJb8h-y4xS4g-vzofotQ/videos
Thrombosis - The formation of a thrombus or blood clot within an intact blood vessel is called thrombosis. Clotting is a normal response that prevents bleeding when a blood vessel wall is injured.
Feeling THROMBOSIS while using ACYCLOVIR? THROMBOSIS Causes, Patient Concerns and Latest Treatments and ACYCLOVIR Reports and Side Effects.
Hi Are we able to predict the points of thrombosis in various conditions? Eg can we pinpoint the high risk plaque, other points with high risk for thrombos...
A stent is provided wherein at least an outer surface portion is roughened to a predetermined extent and wherein a drug or a therapeutic agent can be applied to said surface. This results in an improved stent, which can be manufactured at low costs and which can further avoid thrombus formation and a stenosis.
Professional guide for Ticlopidine. Includes: pharmacology, pharmacokinetics, contraindications, interactions, adverse reactions and more.
TY - JOUR. T1 - Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. T2 - A report from the e-SELECT (Multi-center Post-Market Surveillance) registry. AU - Urban, Philip. AU - Abizaid, Alexandre. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Baux, Ana Cebrian. AU - Davk, Vladimr. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David. AU - Jeong, Myung Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Spaulding, Christian. AU - Worthley, Stephen. PY - 2011/3/29. Y1 - 2011/3/29. N2 - Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated ...
Press Release issued Oct 28, 2012: TechNavios analysts forecast the Global Drug-eluting Stents market to reach US$6,278 million by 2015. One of the key factors contributing to this market growth is the increasing incidence of cardiovascular diseases. The Global Drug-eluting Stents market has also been witnessing the use of bifurcated self-expanding coronary stents. However, the decline in the average selling price of drug-eluting stents could pose a challenge to the growth of this market.
Three year follow-up of patients who received dual antiplatelet therapy (DAPT) after placement of a drug-eluting stent (DES) shows that a short course of the therapy continues to be as beneficial as a longer course.
Management of such patients should start from assessment of the net value of aspirin. This is clear cut for secondary prophylaxis and for some high risk groups29,30 but more widespread use may cause more harm than good.29 Secondly, for those who need aspirin, doses above 100 mg daily are not evidence based and result in increased risk of ulcer bleeding29 (a meta-analysis suggesting no dose dependence109 seems flawed because it compared high dose studies in the 1970s with low dose studies in the 1990s when inclusion criteria differed and reporting of complications was likely to have been more rigorous). If a patient needs aspirin, recent data on the interaction with ibuprofen40 suggests it is unsafe to assume that aspirin would protect against coronary thrombosis in the presence of this drug. Such a patient needing anti-inflammatory medication might benefit from a selective COX-2 inhibitor, not for its gastroprotective effects but for its permissive cardiovascular benefits in allowing aspirin to ...
Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform.
Successful percutaneous transluminal coronary angioplasty (PTCA) was performed on a 37-year-old white man with an isolated 95% right coronary artery stenosis who initially presented with type II unstable angina. Submaximal treadmill stress testing was not carried out before PTCA, but testing 3 days after PTCA was strongly positive without accompanying symptoms of myocardial ischaemia. Some 30 minutes after this test the patient experienced severe precordial pain with features of a hyperacute transmural inferior myocardial infarction. Immediate coronary arteriography delineated fresh thrombus related to the previous PTCA site. Intracoronary thrombolysis with streptokinase was successful, revealing an underlying severe stenosis at the PTCA site. PTCA was not repeated, nor was emergency coronary artery bypass grafting (CABG) performed. This is the second such case documented in the literature; the first patient failed to respond to intracoronary thrombolysis with streptokinase and was submitted to ...
TY - JOUR. T1 - ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). AU - Kim, Jung Sun. AU - Kim, Byeong Kuk. AU - Jang, Ik Kyung. AU - Shin, Dong Ho. AU - Ko, Young Guk. AU - Choi, Donghoon. AU - Hong, Myeongki. AU - Cho, Yun Kyeong. AU - Nam, Chang Wook. AU - Hur, Seung Ho. AU - Choi, Jin Ho. AU - Song, Young Bin. AU - Hahn, Joo Yong. AU - Choi, Seung Hyuk. AU - Gwon, Hyeon Cheol. AU - Jang, Yangsoo. PY - 2012/4/1. Y1 - 2012/4/1. N2 - Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, ...
Thesis, English, ASPIRATION THROMBECTOMY DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION AS ADJUNCTIVE THERAPY TO EARLY (IN AMBULANCE) ABCIXIMAB ADMINISTRATION IN PATIENTS WITH ACUTE ST ELEVATION MYOCARDIAL INFARCTION AN ANALYSIS from LEIDEN MISSION! ACUTE MYOCARDIAL INFARCTION TREATMENT OPTIMIZATION PROGRAM for Ahmed Tarek Abdel Hameed Nagib
Flanagan CM, Kaesberg JL, Mitchell ES, Ferguson MA, Haigney MC (2008). «Coronary artery aneurysm and thrombosis following ... Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ (2007). «Obesity and thrombosis». Eur J Vasc Endovasc Surg. 33 (2): 223- ... 2004). «Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease». N. Engl. J. Med. ... Dentali F, Squizzato A, Ageno W (2009). «The metabolic syndrome as a risk factor for venous and arterial thrombosis». Semin. ...
Venous thrombosis (Talk:Venous thrombosis), Von Hippel-Lindau disease, Von Willebrand disease, Weissenbacher-Zweymüller ... Diseases - Achalasia (T), Acute coronary syndrome, Acute myeloid leukemia (T), Acute liver failure, Acute proliferative ... Cerebral venous sinus thrombosis (T / good article since 17 April 2008), Chronic fatigue syndrome (T, Chronic myelogenous ... Traveller's thrombosis, Tubulointerstitial nephritis and uveitis (T), Tumor lysis syndrome, Vertebral artery dissection (T, ...
"Coronary Heart Disease". Weitz & Luxenberg P.C. Archived from the original on May 30, 2013. Retrieved March 20, 2013.. ... Melasma and thrombosis associated with use of estrogen-containing hormonal contraception, such as the combined oral ...
North American Thrombosis Forum - NATF is a nonprofit organization dedicated to promoting thrombosis research, prevention and ... This may be aided by fibrinolytic drugs such as Tissue Plasminogen Activator (tPA) in instances of coronary artery occlusion. ... "Seminars in Thrombosis and Hemostasis. 43 (2): 154-168. doi:10.1055/s-0036-1586229. PMC 5848490. PMID 27677179.. ... Not to be confused with Embolism or Thrombosis.. A thrombus, colloquially called a blood clot, is the final product of the ...
Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ (2007). "Obesity and thrombosis". Eur J Vasc Endovasc Surg. 33 (2): 223- ... 2006). "The obesity paradox in non-ST-segment elevation acute coronary syndromes: Results from the Can Rapid risk ... Dentali F, Squizzato A, Ageno W (2009). "The metabolic syndrome as a risk factor for venous and arterial thrombosis". Semin. ... 2006). "Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic ...
Thrombosis - Phlebitis - Deep vein thrombosis - Portal vein thrombosis - Venous thrombosis - Budd-Chiari syndrome - ... Coronary artery bypass surgery[mag-edit , alilan ya ing pikuwanan]. Pun bulung: Coronary artery bypass graft surgery ... Coronary artery bypass surgery during mobilization (freeing) of the right coronary artery from its surrounding tissue, adipose ... Thrombus material (in a cup, upper left corner) removed from a coronary artery during a percutaneous coronary intervention to ...
"Thrombosis and Haemostasis. 101 (2): 271-78. doi:10.1160/th08-09-0575. PMID 19190809. Retrieved 19 June 2009.. ... Coronary artery aneurysm. *head / neck *Intracranial aneurysm. *Intracranial berry aneurysm. *Carotid artery dissection ...
North American Thrombosis Forum - NATF is a nonprofit organization dedicated to promoting thrombosis research, prevention and ... This may be aided by fibrinolytic drugs such as Tissue Plasminogen Activator (tPA) in instances of coronary artery occlusion. ... "Seminars in Thrombosis and Hemostasis. 43 (2): 154-168. doi:10.1055/s-0036-1586229. PMC 5848490. PMID 27677179.. ... A thrombus is a healthy response to injury intended to prevent bleeding, but can be harmful in thrombosis, when clots obstruct ...
Skeaff CM, Miller J (2009). "Dietary fat and coronary heart disease: summary of evidence from prospective cohort and randomised ... Thrombosis, and Vascular Biology》 19 (2): 187-195. doi:10.1161/01.atv.19.2.187. PMID 9974397.. ... "A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease". 》Arch. Intern ... "Effects on Coronary Heart Disease of Increasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta- ...
Thrombosis, and Vascular Biology. 24 (1): 29-33. doi:10.1161/01.ATV.0000099786.99623.EF. PMID 14551151.. ... "Adiponectin isoforms in elderly patients with or without coronary artery disease". Journal of the American Geriatrics Society. ... coronary artery disease has been found to be positively associated with high molecular weight adiponectin, but not with low ... "Effect of weight loss on coronary circulation and adiponectin levels in obese women". International Journal of Cardiology. 134 ...
... thrombosis. These changes create an exaggerated layered appearance (onion skinning).[11] ... Coronary artery aneurysm. *head / neck *Intracranial aneurysm. *Intracranial berry aneurysm. *Carotid artery dissection ...
Journal of thrombosis and haemostasis : JTH. 2009-07, 7 (7): 1092-8 [2020-02-12]. PMID 19422446. doi:10.1111/j.1538-7836.2009. ... Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque.. Blood. 2002-04-15, 99 ... Role and mechanism of tissue factor in circulating cell membrane microvesicles in thrombosis. Hainan medical journal. 2019-04, ... Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer ...
CAD · Coronary thrombosis · Coronary vasospasm · Coronary artery aneurysm · Coronary artery dissection · Myocardial Bridge ... Ornish, Dean; एवं अन्य (1990). "'Can lifestyle changes reverse coronary heart disease?' The Lifestyle Heart Trial". Lancet. 336 ... Angina pectoris (Prinzmetal's angina, Stable angina) · Acute coronary (Unstable angina, Myocardial infarction / heart attack) ... Andraws R, Berger JS, Brown DL (2005). "Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a ...
Coronary stents are placed during a coronary angioplasty. The most common use for coronary stents is in the coronary arteries, ... Vascular stents made of metals can lead to thrombosis at the site of treatment or to inflammation scarring. Drug-eluting stents ... The first use of a coronary stent is typically attributed to Jacques Puel [fr] and Ulrich Sigwart when they implanted a stent ... There is a wide variety of stents used for different purposes, from expandable coronary, vascular and biliary stents, to simple ...
"Obesity and thrombosis". Eur J Vasc Endovasc Surg 33 (2): 223-33. February 2007. doi:10.1016/j.ejvs.2006.10.006. பப்மெட்: ... "Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled ...
Thrombosis Research. 1993 Apr 15;70(2):131-8. PMID 8322284 *^ Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, Ito S, ... improves the coronary microcirculation in coronary artery disease. Clinical Cardiology. 2002 Jan;25(1):28-32. PMID 11808836 ... Thrombosis Research. 1996 Dec 15;84(6):445-52. PMID 8987165 *^ Igarashi M, Okuda T, Oh-i T, Koga M. Changes in plasma serotonin ...
Coronary artery aneurysm. *Spontaneous coronary artery dissection (SCAD). *Coronary thrombosis. *Coronary vasospasm ...
Venous thrombosis /. Thrombophlebitis. *primarily lower limb *Deep vein thrombosis. *abdomen *Hepatic veno-occlusive disease ... Coronary artery aneurysm. *head / neck *Intracranial aneurysm. *Intracranial berry aneurysm. *Carotid artery dissection ...
"Coronary calcium as a predictor of coronary events in four racial or ethnic groups". N. Engl. J. Med. 358 (13): 1336-45. doi: ... Thrombus/thrombosis. Renal vein thrombosis. Ischemia. Brain ischemia · Ischaemic heart disease · Ischemic colitis/Mesenteric ... 1995). "Prediction of coronary heart disease using risk factor categories". J Indian Med Assoc. 93 (8): 312-5. PMID 8713248.. ... of a branch of the left coronary artery (LCA, right coronary artery = RCA). ...
Coronary artery aneurysm. *Spontaneous coronary artery dissection (SCAD). *Coronary thrombosis. *Coronary vasospasm ...
"Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (8): 1908-1915. doi:10.1161/ATVBAHA.111.225268. PMC 3141106. Retrieved ... "Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs ischaemia/reperfusion." British Journal of ...
Coronary artery disease[edit]. The primary health risk identified for trans fat consumption is an elevated risk of coronary ... Venous thrombosis /. Thrombophlebitis. *primarily lower limb *Deep vein thrombosis. *abdomen *Hepatic veno-occlusive disease ... November 1997). "Dietary fat intake and the risk of coronary heart disease in women". The New England Journal of Medicine. 337 ... "Trans fatty acids and coronary heart disease". Archived from the original on 3 September 2006. Retrieved 14 September 2006.. ...
en:Coronary artery disease (52) → 관상동맥질환 *en:Coronary catheterization (4). *en:Coronary ischemia (4) ... en:Deep vein thrombosis (27) → 심부정맥 혈전증 *en:Dehydration (55) → 탈수 *en:Delayed puberty (8) → 사춘기지연 ...
Coronary artery aneurysm. *Spontaneous coronary artery dissection (SCAD). *Coronary thrombosis. *Coronary vasospasm ...
It is the second-leading cause of death in non-coronary intensive care unit (ICU) and the tenth-most-common cause of death ... People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other ... Medication to prevent deep vein thrombosis and gastric ulcers also may be used.[8] ...
Russert died on June 13, 2008, of a sudden coronary thrombosis (caused by a cholesterol plaque rupture).[17] Former NBC Nightly ...
Hu, FB; Manson, JE; Willett, WC (2001). "Types of dietary fat and risk of coronary heart disease: A critical review". Journal ... Thrombosis, and Vascular Biology. 23 (2): e20-30. doi:10.1161/01.ATV.0000038493.65177.94. PMID 12588785. Lerman-Garber, I; ... Hu, Frank B.; Willett, WC (2002). "Optimal Diets for Prevention of Coronary Heart Disease". JAMA. 288 (20): 2569-78. doi: ...
Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ (February 2007). "Obesity and thrombosis". Eur J Vasc Endovasc Surg 33 ( ... July 2006). "The obesity paradox in non-ST-segment elevation acute coronary syndromes: Results from the Can Rapid risk ... Dentali F, Squizzato A, Ageno W (July 2009). "The metabolic syndrome as a risk factor for venous and arterial thrombosis". ... 2006). "Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic ...
... can cause a dangerous condition known as deep vein thrombosis (DVT). It develops when a blood clot forms in the leg or thigh ... an ingredient that could increase your chances of developing coronary artery disease.. ...
Whole body scanning, coronary artery calcium scoring, virtual colonoscopy, lung screening, heart scanning-these are the ... as with deep-vein thrombosis). It also helps clinicians assess the health of the arteries before or after a procedure, i.e., to ... Often the first choice procedure after a heart attack, a catheter is threaded into the coronary arteries where a stent or ... This procedure helps evaluate coronary artery disease, acute chest pain, hibernating myocardium and cardiomyopathies. Initially ...
Referred pain - pneumonia, acute coronary syndrome, musculoskeletal, genitalia (torsion of testis), neurogenic ... Deep Venous Thrombosis (Arm). *Deep Venous Thrombosis (Leg). *Headache (Constant or Repeated) ...
They are: coronary heart disease stroke peripheral arterial disease aortic disease Coronary heart disease Coronary heart ... Blood flow to the heart, brain or body can be reduced as the result of a blood clot (thrombosis), or by a build-up of fatty ... in the coronary arteries bệnh viện tim mạch. The coronary arteries are the two major blood vessels that supply your heart with ... Read more about coronary heart disease bác sĩ tim mạch giỏi tphcm. Stroke A stroke is a serious medical condition that occurs ...
Coronary Artery Disease * Diabetic Foot * Intermittent Claudication * Peripheral Arterial Disease * Thrombosis * Cardiac ...
Coronary vascular intervention. BIOFLOW-III Investigating Orsiro drug-eluting coronary stent. Observational trial. 1356. Orsiro ... Swedish Coronary Angiography and Angioplasty Registry. Observational trial. , 270000. Orsiro Drug-Eluting Stent. Coronary ... Coronary vascular intervention. GALAXY Long-term evaluation of the Linox family ICD leads. Observational trial. 1997. Leads ... Coronary vascular intervention. BIOFLOW-II Study of the Orsiro Drug Eluting Stent System. Randomized controlled trial. 440. ...
International Society on Thrombosis and Haemostasis and the American Heart Association Release Scientific Statement Outlining ... Women taking beta blockers for hypertension may have higher risk of heart failure with acute coronary syndrome ...
"But this study suggests doctors were seeing them differently." Coronary bypass surgery involves taking a healthy blood vessel ... The article appeared Thursday in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology. ... including coronary artery disease, stroke, heart failure and peripheral vascular disease. The study found women exposed to ...
Coronary Thrombosis. *Gangrene. *Haematomas. *Haemophilia. *Haemorrhages - capillary or vascular. *Haemorrhoids. *Heart. *Heart ...
... and protection against coronary heart disease A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip Rapid ... to the nanoscale Lysyl oxidase is associated with increased thrombosis and platelet reactivity WNT-SHH antagonism specifies and ... a summary report and call to action ANGPTL3 deficiency and protection against coronary artery disease CRISPR Cas9 epigenome ... a cohort study using electronic primary care records Lutein exerts anti-inflammatory effects in patients with coronary artery ...
He was admitted to the coronary care unit as acute coronary syndrome, non-ST elevation MI and started on ACS medication. ECG ... the main underlying system is graft thrombosis, which is the effect of a mix of diffuse endothelial disruptions, adjustments in ... and coronary artery disease underwent coronary artery bypass graft surgery in 2004 left internal mammary artery to left ... Percutaneous coronary intervention of grafts vessel is more challenging because of June 22, 2017. by Leo Gilbert·0 Comments ...
2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent ... 2.10 Stable angina, acute coronary syndromes and fibrinolysis. *2.11 Antifibrinolytic drugs and haemostatics ... 2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent ...
2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent ... 2.10 Stable angina, acute coronary syndromes and fibrinolysis. *2.11 Antifibrinolytic drugs and haemostatics ... 2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent ... 2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent ...
The typical symptoms of coronary heart disease (CHD), chest pain and breathlessness, are well-known. The diagnosis was made ... Dynamic MR studies of hepatocellular carcinoma with portal vein tumor thrombosis. Three-dimensional conformal external beam ... and may affect on the development of coronary PV. Videotaped mother-child attachment doll play completions of 77 children from ...
Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk ... Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic ... Angina Pectoris Due to Coronary Atherosclerosis. Propranolol hydrochloride tablets, USP are indicated to decrease angina ...
Incidence and Risk Factors for Deep Vein Thrombosis after Radiofrequency and Laser Ablation of the Lower Extremity Veins. ... Aortoiliac elongation over time was not associated with sex (P = 0.3), hypertension (P = 0.7), coronary artery disease (P = 0.3 ... Increased Vertebral Exposure in Anterior Lumbar Interbody Fusion Associated With Venous Injury and Deep Venous Thrombosis Ho, V ... The rates of thromboembolic complications such as deep venous thrombosis (DVT) after venous ablation procedures for symptomatic ...
... and deep vein thrombosis (DVT) in people aged 16 and over ... Acute coronary syndromes. 1.4.1 Be aware that people receiving ... Embolism and thrombosis Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or ... 1.4 Interventions for people with acute coronary syndromes or acute stroke or for acutely ill patients. ... 1.4 Interventions for people with acute coronary syndromes or acute stroke or for acutely ill patients ...
Percutaneous Coronary Intervention) from the American College of Cardiology (ACC) for the third consecutive time. ... and deep vein thrombosis. ...
Intestinal Ischemia / Thrombosis. *Intra-Abdominal Disease (as cause of low back pain) ... Risk Factors for Coronary Artery Disease. *ß-Thalassemia & co-existing Iron Deficiency ...
Gorog, D. & Becker, R., 11 Jun 2020, In : Journal of Thrombosis and Thrombolysis.. Research output: Contribution to journal › ... Platelet inhibition in acute coronary syndrome and PCI: Insights from the past and present. Gorog, D. & Geisler, T., 19 Jan ... Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Bor, W. & Gorog, D., 27 Jun 2020, In ... Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac ...
Coronary Heart Disease. *High Blood Pressure. *Peripheral Arterial Disease. *Ankle Brachial Index ABI ... Deep Vein Thrombosis. *May Thurner Syndrome. *Pelvic Congestion Syndrome. *Venous Angiogram. *Venous Ultrasound ...
To reduce the rate of infection at the saphenous vein harvest site after coronary artery bypass surgery, to identify predictors ... Treatment of cerebral sinus thrombosis with anticoagulants has been controversial. The effect of grouping on the analysis of ... successfully treated with primary percutaneous coronary intervention (pPCI). The structure reveals an unexpected domain ...
Humeral artery thrombosis simulating an elbow monoarthritis in a woman with primary antiphospholipid syndrome (Hughes syndrome ... Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. Taken together ...
Thrombosis UK. "We welcome the data released today that will enable people who have had an unprovoked VTE, or who are at high ... in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late- ...
The ABSORB clinical trial is a non-randomized study with an initial assessment of safety (MACE and stent thrombosis rate) at ... Evaluation of Bioabsorbable Drug Eluting Coronary Stent Underway. March 10th, 2006 Medgadget Editors News ... "With patients receiving an ever-increasing number of coronary stents in more challenging vessel anatomies, we need clinical ... to evaluate the safety of Guidants proprietary fully bioabsorbable everolimus eluting stent for the treatment of coronary ...
  • any improvement in survival statistics were more likely due to prevention of thromboembolic complications (e.g. fatal pulmonary embolism) than in the treatment of the offending coronary artery thrombus itself, and the risk of bleeding sometimes life-threatening, was another consideration. (positivehealth.com)
  • Atrial fibrillation and percutaneous coronary intervention: stroke, thrombosis, and bleeding. (biomedsearch.com)
  • Currently available data suggest that patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with stenting who do not continue oral anticoagulation are at increased risk for mortality and morbidity. (biomedsearch.com)
  • Other causes of coronary embolism include atrial fibrillation, left atrial tumours, bacterial endocarditis, atrial and ventricular mural thrombus, syphilis and pulmonary vein thrombosis . (who.int)
  • Here we review the pharmacology and the results of clinical trials with these new agents in stroke prevention in atrial fibrillation and secondary prevention after acute coronary syndromes, providing perspectives on their future incorporation into clinical practice. (ox.ac.uk)
  • Overall, the new oral anticoagulants are poised to replace vitamin K antagonists for many patients with atrial fibrillation and may have a role after acute coronary syndromes. (ox.ac.uk)
  • In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology , Boekholdt et al 7 provide further evidence that homozygosity for the less common T-allele resulting from a thymidine-to-guanine substitution in the 3′ untranslated region (3′ UTR) of the THBS-2 gene is associated with reduced risk of premature MI. (ahajournals.org)
  • Now, going back in my own personal history, let me tell you of my first observations concerning the blood, which resulted in my conclusions as to how to prevent thromboses, or blood clots. (seleneriverpress.com)
  • In this patient population, therapy directed at reducing both thromboembolism (via oral anticoagulation) and stent thrombosis (via dual antiplatelet therapy) is necessary but is associated with an increased risk for bleeding. (biomedsearch.com)
  • 1 Some notable risk factors for stent thrombosis include the presence of bifurcation and small vessel lesions, suboptimal angiographic results, high-risk patients (i.e., diabetes mellitus and renal failure), and most importantly, cessation of dual antiplatelet therapy (i.e., aspirin and clopidogrel). (apsf.org)
  • The risk of perioperative bleeding associated with antiplatelet therapy must be weighed against the catastrophic event of stent thrombosis from discontinuation of antiplatelet therapy. (apsf.org)
  • Apixaban and rivaroxaban were evaluated in phase III trials for prevention of recurrent ischemia in patients with acute coronary syndromes who were mostly receiving dual antiplatelet therapy, with conflicting results on efficacy but consistent results for increased major bleeding. (ox.ac.uk)
  • In this 1954 article from the legendary health magazine Prevention , Dr. Ernest Klein describes his remarkable discovery of a possible predictor of coronary thrombosis (the cause of most heart attacks) as well as a means of its prevention through a simple dietetic therapy. (seleneriverpress.com)
  • We studied stent thrombosis in 4,607 patients with acute coronary syndromes who received a coronary stent as part of routine care during 2 trials of aspirin versus sibrafiban for secondary prevention. (scripps.edu)
  • The prediction and prevention of coronary thrombosis in the younger age groups, a suggestion for further study. (wizdom.ai)
  • As you already know, this medication is normally used in the prevention of thrombosis and thromboembolism. (steadyhealth.com)
  • There are 4 other drugs that are used in the prevention of thrombosis and thromboembolism: Apixaban (Eliquis)​, Dabigatran (Pradaxa), Edoxaban (Savaysa) and Rivaroxaban (Xarelto). (steadyhealth.com)
  • There are 5 drugs in total that are used in the prevention of thrombosis and thromboembolism. (steadyhealth.com)
  • The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. (naver.com)
  • White arrows indicate the target lesions where the initial PCI was performed, and black arrowheads indicate the lesions responsible for subacute stent thrombosis, respectively. (cdc.gov)
  • Fifty percent of the victims of a "heart attack" (the common name for coronary thrombosis or infarction) survive the attack. (seleneriverpress.com)